Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation

Transplantation

Volumn 94, Issue 8, 2012, Pages 866-872

  Ji, Eunhee ^a   Choi, Leena ^b   Suh, Kyung Suk ^c   Cho, Joo Youn ^d   Han, Nayoung ^d   Oh, Jung Mi ^d  

^a Gachon University College of Medicine   (South Korea)

^b VANDERBILT UNIVERSITY   (United States)

^c Seoul National University Hospital   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

CYP3A5; Donor; Living donor liver transplantation; Recipient; Tacrolimus

Indexed keywords

CORTICOSTEROID; FLUCONAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADULT; AGED; ARTICLE; ASIAN; CONTROLLED STUDY; COVARIANCE; CYP3A5 GENE; DEMOGRAPHY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GENE; GENE EXPRESSION; GENOTYPE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KOREAN; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL;

ADULT; AGED; ALLELES; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; TACROLIMUS;

EID: 84868196047     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318263700a     Document Type: Article

References (28)

1. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404.
2. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 1995; 17: 606.
3. Zheng H, Webber S, Zeevi A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003; 3: 477.
4. Huang W, Lin YS, McConn DJ 2nd, et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 2004; 32: 1434.
5. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383.
6. Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 2006; 112: 184.
7. Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82: 711.
8. Olthoff KM, Merion RM, Ghobrial RM, et al. Outcomes of 385 adultto-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg 2005; 242: 314.
9. Berg CL, Gillespie BW, Merion RM, et al. Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology 2007; 133: 1806.
10. Schiano TD, Kim-Schluger L, Gondolesi G, et al. Adult living donor liver transplantation: the hepatologist's perspective. Hepatology 2001; 33: 3.
11. Wei-lin W, Jing J, Shu-sen Z, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 2006; 12: 775.
12. Yu S, Wu L, Jin J, et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 2006; 81: 46.
13. Uesugi M, Masuda S, Katsura T, et al. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 2006; 16: 119.
14. Fukudo M, Yano I, Yoshimura A, et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008; 18: 413.
15. Demetris AJ, Batts KP, Dhillon AP, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658.
16. Lodewijk L, Mall A, Spearman CW, et al. Effect of liver regeneration on the pharmacokinetics of immunosuppressive drugs. Transplant Proc 2009; 41: 379.
17. Kawasaki S, Makuuchi M, Ishizone S, et al. Liver regeneration in recipients and donors after transplantation. Lancet 1992; 339: 580.
18. Haga J, Shimazu M, Wakabayashi G, et al. Liver regeneration in donors and adult recipients after living donor liver transplantation. Liver Transpl 2008; 14: 1718.
19. Starkel P, Laurent S, Petit M, et al. Early down-regulation of cytochrome P450 3A and 2E1 in the regenerating rat liver is not related to the loss of liver mass or the process of cellular proliferation. Liver 2000; 20: 405.
20. Li D, Lu W, Zhu JY, et al. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther 2007; 32: 505.
21. Jun KR, Lee W, Jang MS, et al. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Transplantation 2009; 87: 1225.
22. Goto M, Masuda S, Kiuchi T, et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 2004; 14: 471.
23. Elens L, Capron A, Kerckhove VV, et al. 1199G9A and 2677G9T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genomics 2007; 17: 873.
24. Jin Z, Zhang WX, Chen B, et al. Stepwise regression analysis of the determinants of blood tacrolimus concentrations in Chinese patients with liver transplant. Med Chem 2009; 5: 301.
25. Yu KS, Cho JY, Jang IJ, et al. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 2004; 76: 104.
26. Diczfalusy U, Miura J, Roh HK, et al. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. 2008; 18: 201.
27. Park SY, Kang YS, Jeong MS, et al. Frequencies of CYP3A5 genotypes and haplotypes in a Korean population. J Clin Pharm Ther 2008; 33: 61.
28. Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2005.